Patents or patients: who loses?

The unprecedented weakening of patent rights in the United States undermines necessary incentives for the discovery and development of innovative medicines.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Timeline of patent-related Supreme Court and Federal Circuit decisions and other critical developments.

References

  1. 1

    Grabowski, H. Nat. Rev. Drug Discov. 7, 479–488 (2008).

    CAS  Article  Google Scholar 

  2. 2

    Herper, M. The truly staggering cost of inventing new drugs <http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/> (10 February 2012).

  3. 3

    Rader, R. Patent law and litigation abuse <http://mcsmith.blogs.com/files/rader-2013-ed-tex-bb-speech.pdf> (1 November 2013).

  4. 4

    Kowalski, S. Patent literature and methodology: WHO model list of essential medicines <http://www.wto.org/english/tratop_e/trips_e/techsymp_feb11_e/kowalski_18.2.11_e.pdf>(18 February 2011).

  5. 5

    KSR International Co. v. Teleflex Inc., 550 US 398 (2007).

  6. 6

    Diamond v. Chakrabarty, 447 US 303 (1980).

  7. 7

    Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 132 S.Ct. 1289 (2012).

  8. 8

    Alice Corporation Pty. Ltd. v. CLS Bank International, 82 L.Ed.2d 296 (2014).

  9. 9

    Association for Molecular Pathology et al., v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013).

  10. 10

    eBay Inc. v. MercExchange, LLC, 547 US 388 (2006).

  11. 11

    Merck KGaA v. Integra Lifesciences I, Ltd., 545 US 193 (2005).

  12. 12

    Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 686 F.3d 1348 (2012).

  13. 13

    Limelight Networks, Inc. v. Akamai Technologies, Inc., 134 S.Ct. 2111 (2014).

  14. 14

    35 USC Section 112.

  15. 15

    Nautilus Inc. v. Biosig Instruments Inc., 134 S.Ct. 2120 (2014).

  16. 16

    Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 US 722 (2002).

  17. 17

    MedImmune, Inc. v. Genentech, Inc., 549 US 118 (2007).

  18. 18

    Rates Technology, Inc. v. Speakeasy, Inc., 685 F.3d 163 (2012).

  19. 19

    Medtronic, Inc. v. Mirowski Family Ventures, LLC, 134 S.Ct. 843 (2014).

  20. 20

    Microsoft Corp. v. i4i Limited Partnership, 131 S.Ct. 2238 (2011).

  21. 21

    Kesselheim, A. N. Engl. J. Med. 363, 1855–1862 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Joanna Brougher or Konstantin M Linnik.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brougher, J., Linnik, K. Patents or patients: who loses?. Nat Biotechnol 32, 877–880 (2014). https://doi.org/10.1038/nbt.3005

Download citation

Further reading